Skip to main content

Dr. Daniel George, M.D.

Urology (Urology Physician)

  • Medicare participating

At a glance

Years since graduation
34
In the NPI registry since
2006
Medicare patients seen, 2024
215

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is

Education and training

  • 1992Medical school: Duke University School of Medicine
  • 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier

Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Urology Physician primary

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Urology per capita by county →

Where they work

Hospitals

Medical groups

Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.

Medicare patients and services

Medicare patients, 2024
215
Services billed
836
Patients’ average age
75
Most frequent Medicare services, 2023
ServiceTimesPatients
Established patient office or other outpatient visit, 40-54 minutes333171
Established patient office or other outpatient visit, 30-39 minutes7657
New patient office or other outpatient visit, 60-74 minutes3434

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Most prescribed drugs, Medicare Part D 2024
DrugPrescriptions
Orgovyx (relugolix)91
Prednisone
Other prescribers in Durham, NC
77
Nubeqa (darolutamide)65
Abiraterone Acetate53
Cabometyx (cabozantinib s-malate)51
Xtandi (enzalutamide)34
Prochlorperazine Maleate
Other prescribers in Durham, NC
29
Lenvima (lenvatinib mesylate)27
Eliquis (apixaban)
Other prescribers in Durham, NC
24
Inlyta (axitinib)19

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 12 companies reported 66 payments worth $157,241 in total to this clinician.

By type
Consulting Fee$152,453
Travel and Lodging$3,695
Food and Beverage$1,093

What the payments were for

Largest payments other than meals
DateCompanyWhat it was forAmount
Jun 3, 2025Bayer HealthCare Pharmaceuticals Inc.
Jun 3, 2025
Consulting Fee
Nubeqa · Oncology
$18,000
Jan 7, 2025Pfizer Inc.
Jan 7, 2025
Consulting Fee
XTANDI · ONCOLOGY
$17,520
May 15, 2025Pfizer Inc.
May 15, 2025
Consulting Fee
XTANDI · ONCOLOGY
$17,420
Oct 16, 2025E.r. Squibb & Sons, L.l.c.
Oct 16, 2025
Consulting Fee$16,578
Dec 17, 2025Pfizer Inc.
Dec 17, 2025
Consulting Fee$11,500
Aug 28, 2025Sumitomo Pharma America, Inc.
Aug 28, 2025
Consulting Fee
ORGOVYX · PROSTATE CANCER
$7,848
Oct 30, 2025Bayer HealthCare Pharmaceuticals Inc.
Oct 30, 2025
Consulting Fee
Nubeqa · Oncology
$6,300
Jul 1, 2025Novartis Pharmaceuticals Corporation
Jul 1, 2025
Consulting Fee$4,250
Jul 7, 2025AstraZeneca UK Limited
Jul 7, 2025
Consulting Fee
LYNPARZA · Oncology
$3,425
Jun 26, 2025Novartis Pharmaceuticals Corporation
Jun 26, 2025
Consulting Fee$3,400
All 48 payments other than meals, newest first
All payments other than meals
DateCompanyWhat it was forAmount
Dec 29, 2025Eisai Inc.
Dec 29, 2025
Consulting Fee
Lenvima · Oncology
$2,910
Dec 19, 2025AstraZeneca Pharmaceuticals LP
Dec 19, 2025
Consulting Fee
Truqap · Oncology
Company’s descriptionResearch Related Service
$2,460
Dec 17, 2025Pfizer Inc.
Dec 17, 2025
Consulting Fee$11,500
Dec 17, 2025AstraZeneca Pharmaceuticals LP
Dec 17, 2025
Consulting Fee
Truqap · Oncology
$3,280
Dec 15, 2025AstraZeneca UK Limited
Dec 15, 2025
Consulting Fee$1,370
Oct 30, 2025Bayer HealthCare Pharmaceuticals Inc.
Oct 30, 2025
Consulting Fee
Nubeqa · Oncology
$6,300
Oct 30, 2025E.r. Squibb & Sons, L.l.c.
Oct 30, 2025
Travel and Lodging
travel to BOSTON, MA
$137
Oct 24, 2025AstraZeneca UK Limited
Oct 24, 2025
Consulting Fee
Truqap · Oncology
$2,050
Oct 16, 2025E.r. Squibb & Sons, L.l.c.
Oct 16, 2025
Consulting Fee$16,578
Sep 29, 2025Bayer HealthCare Pharmaceuticals Inc.
Sep 29, 2025
Consulting Fee
Nubeqa · Oncology
$900
Sep 15, 2025AstraZeneca UK Limited
Sep 15, 2025
Consulting Fee$2,055
Sep 3, 2025E.r. Squibb & Sons, L.l.c.
Sep 3, 2025
Travel and Lodging
travel to Boston, MA
$757
Sep 3, 2025E.r. Squibb & Sons, L.l.c.
Sep 3, 2025
Travel and Lodging
travel to Boston, MA
$387
Sep 2, 2025E.r. Squibb & Sons, L.l.c.
Sep 2, 2025
Travel and Lodging
travel to Boston, MA
$387
Aug 28, 2025Sumitomo Pharma America, Inc.
Aug 28, 2025
Consulting Fee
ORGOVYX · PROSTATE CANCER
$7,848
Aug 21, 2025Bayer HealthCare Pharmaceuticals Inc.
Aug 21, 2025
Consulting Fee$1,800
Aug 12, 2025AstraZeneca UK Limited
Aug 12, 2025
Consulting Fee$2,055
Jul 7, 2025AstraZeneca UK Limited
Jul 7, 2025
Consulting Fee
LYNPARZA · Oncology
$3,425
Jul 1, 2025Novartis Pharmaceuticals Corporation
Jul 1, 2025
Consulting Fee$4,250
Jun 26, 2025Novartis Pharmaceuticals Corporation
Jun 26, 2025
Consulting Fee$3,400
Jun 15, 2025AstraZeneca UK Limited
Jun 15, 2025
Consulting Fee$1,370
Jun 3, 2025Bayer HealthCare Pharmaceuticals Inc.
Jun 3, 2025
Consulting Fee
Nubeqa · Oncology
$18,000
Jun 3, 2025Bayer HealthCare Pharmaceuticals Inc.
Jun 3, 2025
Travel and Lodging
Nubeqa · Oncology · travel to Nashville, TN · in-kind
$865
Jun 3, 2025Bayer HealthCare Pharmaceuticals Inc.
Jun 3, 2025
Travel and Lodging
Nubeqa · Oncology · travel to Nashville, TN · in-kind
$80.55
Jun 3, 2025Bayer HealthCare Pharmaceuticals Inc.
Jun 3, 2025
Travel and Lodging
Nubeqa · Oncology · travel to Nashville, TN · in-kind
$29.90
Jun 2, 2025Bayer HealthCare Pharmaceuticals Inc.
Jun 2, 2025
Travel and Lodging
Nubeqa · Oncology · travel to Nashville, TN · in-kind
$394
Jun 2, 2025Bayer HealthCare Pharmaceuticals Inc.
Jun 2, 2025
Travel and Lodging
Nubeqa · Oncology · travel to Nashville, TN · in-kind
$197
May 23, 2025Bayer HealthCare Pharmaceuticals Inc.
May 23, 2025
Consulting Fee
Nubeqa · Oncology
$900
May 21, 2025Pfizer Inc.
May 21, 2025
Consulting Fee$1,095
May 20, 2025Bayer HealthCare Pharmaceuticals Inc.
May 20, 2025
Consulting Fee$900
May 15, 2025Pfizer Inc.
May 15, 2025
Consulting Fee
XTANDI · ONCOLOGY
$17,420
May 15, 2025AstraZeneca UK Limited
May 15, 2025
Consulting Fee$2,055
May 15, 2025AstraZeneca UK Limited
May 15, 2025
Consulting Fee$2,055
May 6, 2025AstraZeneca Pharmaceuticals LP
May 6, 2025
Consulting Fee$902
Apr 28, 2025Bayer HealthCare Pharmaceuticals Inc.
Apr 28, 2025
Consulting Fee$2,700
Apr 14, 2025AstraZeneca UK Limited
Apr 14, 2025
Consulting Fee
Truqap · Oncology
$685
Apr 8, 2025AstraZeneca Pharmaceuticals LP
Apr 8, 2025
Consulting Fee
Truqap · Oncology
Company’s descriptionResearch Related Service
$2,460
Apr 3, 2025AstraZeneca Pharmaceuticals LP
Apr 3, 2025
Consulting Fee
Truqap · Oncology
Company’s descriptionResearch Related Service
$2,050
Mar 25, 2025Novartis Pharmaceuticals Corporation
Mar 25, 2025
Consulting Fee
PLUVICTO · Oncology
$2,550
Mar 15, 2025AstraZeneca UK Limited
Mar 15, 2025
Consulting Fee$1,370
Mar 10, 2025Merck Sharp & Dohme LLC
Mar 10, 2025
Travel and Lodging
travel to Dallas, TX
Company’s descriptionProvided as part of a research engagement.
$300
Mar 5, 2025AstraZeneca UK Limited
Mar 5, 2025
Consulting Fee
LYNPARZA · Oncology
$685
Jan 27, 2025Novartis Pharmaceuticals Corporation
Jan 27, 2025
Consulting Fee
PLUVICTO · Oncology
$1,700
Jan 16, 2025Bayer HealthCare Pharmaceuticals Inc.
Jan 16, 2025
Consulting Fee
Nubeqa · Oncology
$1,800
Jan 15, 2025AstraZeneca UK Limited
Jan 15, 2025
Consulting Fee$1,028
Jan 15, 2025AstraZeneca UK Limited
Jan 15, 2025
Consulting Fee$1,028
Jan 15, 2025Merck Sharp & Dohme LLC
Jan 15, 2025
Travel and Lodging
travel to DALLAS, TX
Company’s descriptionProvided as part of a research engagement.
$160
Jan 7, 2025Pfizer Inc.
Jan 7, 2025
Consulting Fee
XTANDI · ONCOLOGY
$17,520

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in North Carolina →

Industry-funded research

Named as a principal investigator on 11 industry-funded studies in 2025, from 6 companies. The companies reported $2,907,763 in research payments for these studies, mostly to the institutions running them.

  • A prospective observational study to aSSEss the rapidly changing TherapY landscape for Renal Cell Carcinoma (ODYSSEY RCC)
    Exelixis Inc.
  • International Registry for Men with Advanced Prostate Cancer
    Novartis Pharmaceuticals Corporation
  • Outcomes Database to prospectivelY aSSEss changing TherapY landscape in Renal Cell Carcinoma (ODYSSEY RCC)
    E.r. Squibb & Sons, L.l.c.
  • Trimodality Approach to Unfavorable Localized Prostate Cancer: a prospective trial of Neoadjuvant Pembrolizumab, ADT, and Prostate SBRT followed by Radical Prostatectomy (TALON)
    Merck Sharp & Dohme LLC
  • A Phase II open label Multi Center study of Apalutamide Abiraterone Acetate and Prednisone in African American and Caucasian men with metastatic castrate resistant prostate cancer
    Janssen Research & Development, LLC
  • A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors
    Exelixis Inc.
  • A Phase IV, Post-Authorization Safety Study to Investigate the Long-Term Safety of lutetium (177Lu) vipivotide tetraxetan in Adult Participants with Prostate Cancer
    Novartis Pharmaceuticals Corporation
  • A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib Abiraterone Versus Placebo Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensiti…
    AstraZeneca Pharmaceuticals LP
  • A Phase 2 Efficacy and Safety Study of Niraparib in Men With Metastatic Castration Resistant Prostate Cancer and DNA Repair Anomalies
    Janssen Research & Development, LLC
  • An Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care, Versus Standard of Care Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
    Novartis Pharmaceuticals Corporation

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Urology clinicians in Durham

Sources

NPI registry (CMS NPPES, November 2026; record last updated July 8, 2007), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1124101381. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.